Literature DB >> 26272073

Measurement of anti-drug antibodies to biologic drugs.

Anna Felis-Giemza1, Robert J Moots2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26272073     DOI： 10.1093/rheumatology/kev279

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  5 in total

1.  Long-term efficacy of infliximab treatment and the predictors of treatment outcomes in patients with refractory uveitis associated with Behçet's disease.

Authors:  Sho Ueda; Mitsuteru Akahoshi; Atsunobu Takeda; Yasushi Inoue; Aya Omoto; Masahiro Ayano; Yasutaka Kimoto; Hiroki Mitoma; Yojiro Arinobu; Hiroaki Niiro; Hiroshi Tsukamoto; Takahiko Horiuchi; Shin-Ichi Hikita; Takako Fukuhara; Tatsuro Ishibashi; Koh-Hei Sonoda; Koichi Akashi
Journal:  Eur J Rheumatol       Date:  2018-03

2.  Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.

Authors:  Carla Bastida; Virginia Ruiz-Esquide; Mariona Pascal; Aurelia H M de Vries Schultink; Jordi Yagüe; Raimon Sanmartí; Alwin D R Huitema; Dolors Soy
Journal:  Br J Clin Pharmacol       Date:  2018-02-07       Impact factor: 4.335

3.  [Uveitis in juvenile idiopathic arthritis].

Authors:  I Foeldvari; K Walscheid; A Heiligenhaus
Journal:  Z Rheumatol       Date:  2017-10       Impact factor: 1.372

Review 4.  Approaches for the detection and analysis of antidrug antibodies to biopharmaceuticals: A review.

Authors:  Kyungah Suh; Isaac Kyei; David S Hage
Journal:  J Sep Sci       Date:  2022-03-10       Impact factor: 3.614

5.  Anti-IL-7 receptor α monoclonal antibody (GSK2618960) in healthy subjects - a randomized, double-blind, placebo-controlled study.

Authors:  Joanne Ellis; Andre van Maurik; Lea Fortunato; Sophie Gisbert; Keguan Chen; Ann Schwartz; Simon McHugh; Andrew Want; Sara Santos Franco; Joao-Joaquim Oliveira; Jeffrey Price; Alasdair Coles; Kim Brown; Donggang Su; Jenny L Craigen; Jiansong Yang; Sara Brett; Bill Davis; Joseph Cheriyan; Onajite Kousin-Ezewu; Frank Gray; Paul W Thompson; Disala Fernando
Journal:  Br J Clin Pharmacol       Date:  2018-12-03       Impact factor: 4.335
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.